https://charts.traderzeitung.de/phases/US15673T1007 string(1400) "{"isin":"US15673T1007","name":"Century Therapeutics Inc","stock_id_xnas":22560591,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.86,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.91,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":2.6882},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.77,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-7.3298},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Century Therapeutics Aktie News & Nachrichten

[WKN: A3CSHU | Symbol: IPSC]

Realtimekurs

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Century Therapeutics gefunden werden.

Century Therapeutics Nachrichtenticker öffnen

MT Newswires 04.06.2026 12:57 Uhr

Century Therapeutics Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Mizuho nimmt die Berichterstattung für Century Therapeutics mit 'Outperform' auf

Update: Mizuho nimmt Century Therapeutics mit 'Outperform' und einem Kursziel von $8 auf

Mizuho nimmt die Coverage für Century Therapeutics mit 'Outperform' auf